Shu Feng

Shu Feng

Auto-generated profile, based on publicly available information

Shu Feng

Research Division, Chugai Pharmabody Research, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Small-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all patients with SCLC are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation. We demonstrated that DLL3 trispecific induced better tumor growth control and a marked increase in the number of intratumoral T cells compared with a conventional DLL3-targeted bispecific T-cell engager. These findings suggest that DLL3 trispecific can exert potent efficacy by inducing concurrent CD137 costimulation and provide a promising therapeutic option for SCLC.

17 June 2026
Verified
Other
Open access
PDF file
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Supplementary Figure S7. DLL3 expression of SCLC xenograft models.

17 June 2026
Verified
Other
Open access
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Supplementary Figure S3. Binding of DLL3 trispecific to FcγRs, C1q, and FcRn. (

17 June 2026
Verified
Other
Open access
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Supplementary Figure S1. The composition of the antibodies

17 June 2026
Verified
Other
Open access
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys

17 June 2026
Verified
Other
Open access
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Supplementary Figure S5. DLL3 trispecific induces cytotoxicity against non-SCLC tumors.